DSGN Design Therapeutics, Inc.
P/E
--
Forward P/E
-6.387645
Price/Sales
--
Beta
1.686
Div Yield
0.0%
Market Cap
--
Company Analysis
Latest News
Design Therapeutics reports third quarter 2026 EPS beat and upcoming Friedreich ataxia updates
Design Therapeutics reported zero revenue and a third quarter 2026 net loss of $20.3 million, which resulted in a per-share loss that was narrower than...
Design Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Analysts anticipate a Q3 2026 net loss of $0.38 per share on zero revenue, while the stock currently trades at $10.68—well below the average analyst price...